Eupraxia Reports Strong Positive Phase 1b/2a Data for EoE Drug EP-104GI, Showing Near-Complete Tissue Health Improvement

summarizeSummary

Eupraxia Pharmaceuticals reported positive Phase 1b/2a clinical trial data for its EoE drug EP-104GI, showing near-complete tissue health improvement and sustained clinical remission with a favorable safety profile.

check_boxKey Events

• Positive Tissue Health Data

  The highest dose of EP-104GI achieved near-complete normalization of tissue health at 12 weeks in the RESOLVE trial for Eosinophilic Esophagitis (EoE), with lower doses maintaining improvements for up to 36 weeks.

• Sustained Clinical Remission

  Clinical remission was achieved by 8 weeks and maintained through 52 weeks in a majority of patients who had at least 60% of their esophagus treated with EP-104GI.

• Favorable Safety Profile

  Over 200 patient-months of follow-up reported no Serious Adverse Events (SAEs) or cases of oral candidiasis, indicating EP-104GI was well tolerated at all dose levels.

• Advancing to Phase 2b

  The Phase 2b part of the RESOLVE trial is actively recruiting, with top-line data anticipated in Q3 2026.

auto_awesomeAnalysis

Eupraxia Pharmaceuticals announced highly positive 12-week and 36-week tissue health data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis (EoE). The highest dose achieved near-complete normalization of tissue health, with lower doses maintaining improvements for up to 36 weeks. The drug also demonstrated clinical remission maintained through 52 weeks in a majority of patients and a strong safety profile with no serious adverse events. This data significantly de-risks the EP-104GI program and provides strong validation for its potential as a once-yearly treatment for EoE, a condition with high unmet medical need. The positive results reinforce the stock's current position near its 52-week high. Investors should monitor the progress of the ongoing Phase 2b trial, with top-line data expected in Q3 2026.